These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30303110)

  • 1. CAR T-cell therapy: perceived need versus actual evidence.
    The Lancet Oncology
    Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities associated with immunotherapies for hematologic malignancies.
    Leick MB; Maus MV
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.
    Valand HA; Huda F; Tu RK
    AJNR Am J Neuroradiol; 2019 May; 40(5):766-768. PubMed ID: 31048298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cells, immunologic and cellular therapies in hematologic malignancies.
    Brentjens R; Davila ML
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):115-116. PubMed ID: 29909911
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
    Prasad V
    Nat Rev Clin Oncol; 2018 Jan; 15(1):11-12. PubMed ID: 28975930
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cell therapy for haematological malignancies.
    Selim AG; Tam CS
    Med J Aust; 2020 Nov; 213(9):404-406.e1. PubMed ID: 32951222
    [No Abstract]   [Full Text] [Related]  

  • 13. Safer CAR T-Cell Therapy.
    Abbasi J
    JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
    [No Abstract]   [Full Text] [Related]  

  • 14. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
    Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
    Murad JM; Graber DJ; Sentman CL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):176-183. PubMed ID: 29909918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
    Zhou D; Zhu X; Xiao Y
    Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.
    Mochel JP; Ekker SC; Johannes CM; Jergens AE; Allenspach K; Bourgois-Mochel A; Knouse M; Benzekry S; Wierson W; LeBlanc AK; Kenderian SS
    AAPS J; 2019 Apr; 21(3):50. PubMed ID: 30963322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Rubio MT; Galaine J; Borg C; Daguindau É
    Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.